MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 585135 | Name: Domitroban

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Domitroban, also known as S-145, is a thromboxane (Tx) A2-receptor antagonist with partial agonistic activity in vascular smooth muscle.

Chemical Structure

Domitroban
Domitroban
CAS#112966-96-8

Theoretical Analysis

MedKoo Cat#: 585135

Name: Domitroban

CAS#: 112966-96-8

Chemical Formula: C20H27NO4S

Exact Mass: 377.1661

Molecular Weight: 377.50

Elemental Analysis: C, 63.63; H, 7.21; N, 3.71; O, 16.95; S, 8.49

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Domitroban, S 145, S-145, S145, S-1452
IUPAC/Chemical Name
5-Heptenoic acid, 7-(3-((phenylsulfonyl)amino)bicyclo(2.2.1)hept-2-yl)-, (1R-(1alpha,2alpha(Z),3beta,4alpha))-
InChi Key
PWTCIBWRMQFJBC-ZEMKZVSASA-N
InChi Code
InChI=1S/C20H27NO4S/c22-19(23)11-7-2-1-6-10-18-15-12-13-16(14-15)20(18)21-26(24,25)17-8-4-3-5-9-17/h1,3-6,8-9,15-16,18,20-21H,2,7,10-14H2,(H,22,23)/b6-1-/t15-,16+,18+,20+/m1/s1
SMILES Code
O=C(O)CCC/C=C\C[C@H]1[C@](C2)([H])CC[C@]2([H])[C@@H]1NS(=O)(C3=CC=CC=C3)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 377.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Ushikubi F, Nakajima M, Yamamoto M, Ohtsu K, Kimura Y, Okuma M, Uchino H, Fujiwara M, Narumiya S. [3H]S-145 and [125I]I-S-145-OH: new radioligands for platelet thromboxane A2 receptor with low nonspecific binding and high binding affinity for various receptor preparations. Eicosanoids. 1989;2(1):21-7. PubMed PMID: 2534469. 2: Takasuka M, Yamakawa M, Ohtani M. FTIR spectral study of intramolecular hydrogen bonding in thromboxane A2 receptor antagonist S-145 and related compounds. 3. Conformation and activity of S-145 analogues. J Med Chem. 1991 Jun;34(6):1885-91. PubMed PMID: 1829486. 3: Nakajima M, Ueda M. Actions of a novel thromboxane A2-receptor antagonist, S-145, on isolated monkey and cat arteries. J Cardiovasc Pharmacol. 1989 Sep;14(3):502-9. PubMed PMID: 2476633. 4: Mihara S, Hara S, Ueda M, Ide M, Fujimoto M. Antagonistic actions of S-145 on vascular and platelet thromboxane A2 receptors. Eur J Pharmacol. 1989 Nov 21;171(2-3):179-87. PubMed PMID: 2533558. 5: Yamaguchi Y, Kirita S, Baba T, Aoyama J, Touchi A, Tukey RH, Guengerich FP, Matsubara T. Identification of rat and human cytochrome P450 forms involved in the metabolism of the thromboxane A2 receptor antagonist (+)-S-145. Drug Metab Dispos. 1997 Jan;25(1):75-80. PubMed PMID: 9010633. 6: Hanasaki K, Arita H. Characterization of a new compound, S-145, as a specific TXA2 receptor antagonist in platelets. Thromb Res. 1988 May 1;50(3):365-76. PubMed PMID: 2839912. 7: Kishino J, Hanasaki K, Nagasaki T, Arita H. Kinetic studies on stereospecific recognition by the thromboxane A2/prostaglandin H2 receptor of the antagonist, S-145. Br J Pharmacol. 1991 Aug;103(4):1883-8. PubMed PMID: 1833018; PubMed Central PMCID: PMC1908203. 8: Otani K, Shima N, Doteuchi M. [Pharmacological actions of S-145, a novel thromboxane A2 antagonist, in various smooth muscles]. Nihon Yakurigaku Zasshi. 1989 Nov;94(5):319-28. Japanese. PubMed PMID: 2613111. 9: Arimura A, Miwa M, Hasegawa H, Kishino J, Notoya M, Yasui K, Komori M, Iwata S. Characterization and localization of thromboxane A2 receptor in human and guinea-pig nasal mucosa using radiolabelled (+)-S-145. Br J Pharmacol. 1998 Jun;124(4):795-803. PubMed PMID: 9690873; PubMed Central PMCID: PMC1565454. 10: Yamaguchi Y, Baba T, Touchi A, Matsubara T. In vitro studies to elucidate the metabolic pathway of (+)-S-145, a thromboxane A2 receptor antagonist, in rats. Evidence for two independent pathways in peroxisomal beta-oxidation. Drug Metab Dispos. 1995 Nov;23(11):1195-201. PubMed PMID: 8591718. 11: Li BY, Qiao GF, Sun JP, Gao YR, Li WH. Inhibitory effects of ONO-3708 and S-145 on shape change and aggregation of rabbit platelets induced by STA2. Zhongguo Yao Li Xue Bao. 1996 Jul;17(4):345-8. PubMed PMID: 9812720. 12: Dubé GP, Jakubowski JA, Brune KA, Bemis KG, Kurtz WL. In vivo effects of a novel thromboxane A2/prostaglandin H2 (TXA2/PGH2) partial agonist, (+)5(Z)-7-[3-endo-phenylsulfonylamino[2.2.1]- bicyclohept-2-exo-yl]-heptenoic acid [(+)-S-145], on vascular, platelet and cardiac function. J Pharmacol Exp Ther. 1995 Feb;272(2):799-807. PubMed PMID: 7853197. 13: Dubé GP, Mais DE, Jakubowski JA, Brune KA, Utterback BG, True TA, Rinkema LE, Kurtz WL. In vitro characterization of a novel TXA2/PGH2 receptor ligand (S-145) in platelets and vascular and airway smooth muscle. J Pharmacol Exp Ther. 1992 Aug;262(2):784-91. PubMed PMID: 1386888. 14: Hanasaki K, Nagasaki T, Arita H. Characterization of platelet thromboxane A2/prostaglandin H2 receptor by a novel thromboxane receptor antagonist, [3H]S-145. Biochem Pharmacol. 1989 Jun 15;38(12):2007-17. PubMed PMID: 2525906. 15: Hori Y, Hatakeyama H, Yamada K, Kurosawa A. Effect of a novel thromboxane A2 receptor antagonist, S-145, on collagen-induced ECG changes and thrombocytopenia in rodents. Jpn J Pharmacol. 1989 Jun;50(2):195-205. PubMed PMID: 2528013. 16: Kakushi H, Shike T, Hayasaki Y, Arita H, Uchida K. [Effect of (+)-S-145 calcium salt dihydrate, an orally active antagonist of the thromboxane A2/prostaglandin endoperoxide receptor, on platelet aggregation]. Nihon Yakurigaku Zasshi. 1991 Aug;98(2):113-20. Japanese. PubMed PMID: 1916541. 17: Yamaguchi Y, Touchi A, Baba T, Matsubara T. Species differences in beta-oxidative metabolism of a thromboxane A2-receptor antagonist [(+)-S-145] in rat, dog and monkey. Xenobiotica. 2001 Mar;31(3):125-33. PubMed PMID: 11465390. 18: Ushikubi F, Nakajima M, Hirata M, Okuma M, Fujiwara M, Narumiya S. Purification of the thromboxane A2/prostaglandin H2 receptor from human blood platelets. J Biol Chem. 1989 Oct 5;264(28):16496-501. PubMed PMID: 2528545. 19: Kakushi H, Shike T, Uchida K. [Effect of a new thromboxane A2 antagonist, S-145, on platelet aggregation]. Nihon Yakurigaku Zasshi. 1989 Mar;93(3):171-8. Japanese. PubMed PMID: 2731807. 20: Higaki J, Tonda K, Takahashi S, Hirata M. Metabolism of a thromboxane A2 antagonist in isolated rat hepatocytes. Biomed Environ Mass Spectrom. 1989 Dec;18(12):1057-62. PubMed PMID: 2611419.